Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/3/2012

SAN DIEGO, May 3, 2012  /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2012.

During the first quarter of 2012, Cadence reported net product revenue of $8.0 million, an increase of $7.6 million as compared to the first quarter of 2011. As compared to the quarter ended December 31, 2011, net product revenue for the first quarter of 2012 increased $2.1 million, or 36%, from $5.9 million.

As of March 31, 2012, approximately 2,700 unique accounts had ordered OFIRMEV® (acetaminophen) injection, an increase of approximately 20% quarter-over-quarter, and an estimated 330,000 to 410,000 patients were treated with OFIRMEV in just the first three months of 2012.

"Demand for OFIRMEV continued to grow at a strong pace in the first quarter, and I am encouraged by the underlying trends. Our customer base has increased and our customers made larger orders of the product as compared to the previous quarter," said Ted Schroeder, President and CEO of Cadence. "Our team is focused on expanding on these positive trends and driving continued adoption and revenue growth of OFIRMEV."

Cadence believes that returns related to the voluntary recall of a single lot of OFIRMEV that was announced in February 2012 have been substantially completed. While some customers experienced a short-term supply delay as a result of the temporary suspension of shipments from the supplier of the recalled lot, the company was able to accelerate the delivery of product from another supplier and quickly resumed normal shipments.

Financial ResultsNet product revenue was $8.0 million for the three months ended
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
2. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
3. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
4. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
5. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
8. Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
9. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
10. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), a ... in respiratory critical care, will hold a conference call ... its March 6th announcement that SURFAXIN (lucinactant) has been ... Distress Syndrome (RDS) in premature infants at high risk ...
Cached Medicine Technology:Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant) 2
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/17/2014)... of chronic inflammation in benign prostate tissue was ... this association was found even in those with ... study published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. , An analysis of prostate ... placebo arm of the Prostate Cancer Prevention Trial ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... the Hebrew University of Jerusalem have discovered that Vav1 ... one of the factors in tumorous tissue growth -- plays ... previously been thought. The discovery has implications for further concentration ... work of the researchers, led by Dr. Shulamit Katzav-Shapira of ...
... 2010) International experts and scientists will present ... life of stockpiled drugs to identifying unlabeled substances ... of the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical ... American Association of Pharmaceutical Scientists (AAPS) Annual Meeting ...
... , MONDAY, Nov. 8 (HealthDay News) -- A new ... can be inherited. As part of the Framingham Foot ... participants between 2002 and 2005, researchers studied 675 people ... towards the smaller toes (known as hallux valgus), and 154 ...
... an electrical switch allows the flow of electricity into electrical ... optical switch allowing the flow of light through otherwise opaque ... Los Alamos National Laboratory delivers a 200 terawatt power pulse ... States) in half a trillionth of a second (picosecond) time. ...
... study suggests joint complaints attributed to aromatase inhibitors (AI), ... arthritis or autoimmune disease. Because of that, researchers ... of arthritis should be encouraged to continue taking the ... Tuesday, Nov. 9 at the 74th Annual Scientific Meeting ...
... GA Lupus puts children at higher risk for ... using statins doesn,t provide enough benefit to warrant their ... largest study of pediatric lupus patients to date. ... and organ damage. Children with lupus show early signs ...
Cached Medicine News:Health News:Hebrew University researchers discover expanded role for cancer-causing gene 2Health News:Common Foot Disorders Can Be Inherited, Research Shows 2Health News:Plasma as a fast optical switch 2Health News:Joint pain linked to breast cancer drug not inflammatory arthritis or autoimmune disease 2Health News:Statins don't prove useful for general pediatric lupus population 2
Eliminate preanalytical errors with automated QC module....
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
... Submit your analyzer data via the ... a worldwide peer group. , ... you to perform statistical analysis of ... often as you like. Peer-group data ...
Automated QC module...
Medicine Products: